Lyell Immunopharma expects 2027 FDA End-of-Phase 1 meeting for LYL273 colorectal cancer trial
LYEL•Trial enrollment and next clinical steps
The Phase 1/2 trial continues enrollment to set a recommended Phase 2 dose and refine safety management, using product made at LyFE. Earlier results were already described as encouraging clinical activity, without new efficacy updates in this announcement.
Manufacturing transfer completed for LYL273
Lyell Immunopharma completed a manufacturing transfer for LYL273, its GCC-targeted CAR T-cell candidate for metastatic colorectal cancer.
2027 data update and FDA meeting planned
Additional clinical data will be presented in 2027, alongside an End-of-Phase 1 FDA meeting planned for that year.
